News
-
-
PRESS RELEASE
Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
Carl Zeiss Meditec AG achieved 1.0% revenue growth in the first quarter of fiscal year 2023/24, reaching €475.0m. Earnings before interest and taxes (EBIT) declined to around €43.5m, with the EBIT margin at 9.2%. Revenue growth was primarily boosted by the equipment business and SBU Microsurgery -
-
PRESS RELEASE
Wenchang, Hainan Takes Flight as the Visionary 'City of the Future' Igniting a Thriving Aerospace Industry
Wenchang, China, is experiencing a surge in space-themed tourism, with the Long March-7 Y8 launch making it popular. The city has seen increased tourism, job creation, and economic growth due to its aerospace industry -
PRESS RELEASE
duPont REGISTRY Group Welcomes Colleen Cash as President of Sotheby's Motorsport and Chief Digital Officer of duPont REGISTRY Group
duPont REGISTRY Group and RM Sotheby's appoint Colleen Cash as President of Sotheby's Motorsport and Chief Digital Officer of duPont REGISTRY Group, creating a cohesive experience for both platforms, marking a significant milestone in duPont REGISTRY Group's commitment to elevating the luxury automotive marketplace -
-
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Stock Option Grant
Intellipharmaceutics International Inc. issued 1,910,000 common share purchase options to certain eligible individuals under the stock option plan. The options vest over a period of 2 years and expire on February 5, 2034 -
-
PRESS RELEASE
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
Applied DNA Sciences, Inc. (NASDAQ:APDN) announces Q1 fiscal year 2024 financial results and progress on GMP production capacity for mRNA therapeutics. Projects initial facility capacity to enable up to $15 million Linea IVT revenue annually -
PRESS RELEASE
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Tryp Therapeutics, Inc. obtains interim court order for proposed arrangement with Exopharm Limited ACN 163 765 991. Meeting scheduled for March 8, 2024, in Toronto, Ontario, to vote on the arrangement resolution
